Anjarium Biosciences AG announced that it has received CHF 55.5 million in a round of funding co-led by new investors Abingworth LLP and GIMV NV on September 16, 2021. The transaction also included participation from Omega Fund Management, LLC, Pfizer Venture Investments LLC and Citadel Multi-Strategy Equities Master Fund Ltd., a fund managed by Citadel Advisors LLC. Bali Muralidhar from Abingworth LLP, Bram Vanparys from GIMV NV and Dina Chaya from Omega Fund Management, LLC will join the company's board of directors.